In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biogen/Elan Submit Applications For Tysabri Label Change Ahead of Schedule

This article was originally published in The Pink Sheet Daily

Executive Summary

In a bid to solidify Tysabri's place in an increasingly competitive market, Biogen/Elan push forward with changes to the multiple sclerosis medicine's label that help define the risk of a rare brain infection.
Advertisement

Related Content

Tysabri Usage Restrictions Likely To Remain Stable As FDA Considers REMS Modifications
U.S. Tysabri Labeling Updated With More PML Risk Info But No Reference To JCV Testing
Biogen Continues To Plot New Course In Naming Two Key Executives – But Is Independence Part Of The Plan?
Biogen Continues To Plot New Course In Naming Two Key Executives. But Is Independence Part Of The Plan?
Gilenya Could Surpass Avonex Market Share, Analysts Say
Biogen Idec Lays Off 13 Percent of Staff, Retrenches Around Multiple Sclerosis
Biogen Idec Lays Off 13 Percent of Staff, Retrenches Around Multiple Sclerosis
With Third Quarter Results, Biogen Idec Continues to Ride Its Warhorse Avonex
KRAS Testing Gets On Label Of EGFr Products; Will Tests Get To Clinic Soon?
Icahn Wins Two Seats On Biogen Idec’s Board

Topics

Advertisement
UsernamePublicRestriction

Register

PS071655

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel